Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Efficacy and plasma drug concentrations with nondaily dosing of rosuvastatin.

Goldberg AS, DeGorter MK, Ban MR, Kim RB, Hegele RA.

Can J Cardiol. 2013 Aug;29(8):915-9. doi: 10.1016/j.cjca.2012.12.015.

PMID:
23465343
2.

Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance.

Backes JM, Venero CV, Gibson CA, Ruisinger JF, Howard PA, Thompson PD, Moriarty PM.

Ann Pharmacother. 2008 Mar;42(3):341-6. doi: 10.1345/aph.1K604.

PMID:
18285559
3.

Monday, Wednesday, and Friday dosing of rosuvastatin in patients previously intolerant to statin therapy.

Mackie BD, Satija S, Nell C, Miller J 3rd, Sperling LS.

Am J Cardiol. 2007 Jan 15;99(2):291.

PMID:
17223437
4.

Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.

Meek C, Wierzbicki AS, Jewkes C, Twomey PJ, Crook MA, Jones A, Viljoen A.

Curr Med Res Opin. 2012 Mar;28(3):371-8. doi: 10.1185/03007995.2012.657302.

PMID:
22256801
5.

Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.

Kennedy SP, Barnas GP, Schmidt MJ, Glisczinski MS, Paniagua AC.

J Clin Lipidol. 2011 Jul-Aug;5(4):308-15. doi: 10.1016/j.jacl.2011.03.454.

PMID:
21784377
6.
7.
8.

Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.

Bullano MF, Kamat S, Wertz DA, Borok GM, Gandhi SK, McDonough KL, Willey VJ.

Am J Health Syst Pharm. 2007 Feb 1;64(3):276-84.

PMID:
17244877
9.

Alternate day dosing of rosuvastatin: potential usefulness in statin-intolerant patients.

Joy T, Hegele RA.

Can J Cardiol. 2009 Aug;25(8):453. No abstract available.

10.

Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers.

Li JJ, Yang P, Liu J, Jia YJ, Li ZC, Guo YL, Wu NQ, Tang YD, Jiang LX.

Clin Chim Acta. 2012 Jan 18;413(1-2):139-42. doi: 10.1016/j.cca.2011.09.006.

PMID:
21983163
11.

Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.

Capuzzi DM, Morgan JM, Carey CM, Intenzo C, Tulenko T, Kearney D, Walker K, Cressman MD.

Prev Cardiol. 2004 Fall;7(4):176-81.

12.
13.

Efficacy and safety of rosuvastatin in treatment of dyslipidemia.

McKenney JM.

Am J Health Syst Pharm. 2005 May 15;62(10):1033-47. Review.

PMID:
15901588
14.

Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.

Catapano AL, Davidson MH, Ballantyne CM, Brady WE, Gazzara RA, Tomassini JE, Tershakovec AM.

Curr Med Res Opin. 2006 Oct;22(10):2041-53.

PMID:
17022864
15.

Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).

Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C.

Am J Cardiol. 2011 Aug 15;108(4):523-30. doi: 10.1016/j.amjcard.2011.03.079.

PMID:
21596364
16.

Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.

Gadarla M, Kearns AK, Thompson PD.

Am J Cardiol. 2008 Jun 15;101(12):1747-8. doi: 10.1016/j.amjcard.2008.02.061.

PMID:
18549851
17.

Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.

Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ.

Pharmacotherapy. 2006 Apr;26(4):469-78.

PMID:
16553504
18.
20.

Nondaily statin dosing: mechanisms of a potentially important approach to dealing with statin intolerance.

Pollak PT.

Can J Cardiol. 2013 Aug;29(8):895-8. doi: 10.1016/j.cjca.2013.03.013. No abstract available.

PMID:
23890473
Items per page

Supplemental Content

Support Center